Ochre Bio
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Oxford, Oxfordshire, United KingdomWebsite
www.ochre-bio.comRevenue
$7.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. The company uncover new biological pathways by using advances in 'deep phenotyping', and then study the company's medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines the company brings to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford's biotech innovation hub, Ochre is built on over fifteen years experience in liver genomics and bringing advanced therapies to market.Explore more
Ochre Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ochre Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Ochre Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ochre Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ochre Bio
Click to see if Ochre Bio had a recent Job posting/layoffs
Check out if Ochre Bio is spiking on competitors!
Check if Ochre Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ochre Bio launches new products
Funding: Get notified immidiatlly once Ochre Bio has new funding data
Recommended Actions
Reach out to Masked Content who joined Ochre Bio as Masked Content
Find more new buyers
Compare Similar Companies to Ochre Bio
Compare insights from companies similar to Ochre Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ochre Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ochre Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ochre Bio.
Ochre Bio financials insights
Gather financial insights about Ochre Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$9.6M
2022
Series A
$30M
Ochre Bio Tech Stack
A closer look at the technologies used by Ochre Bio
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
New Hire
Executive Move
Event
Events, Information Security, Engineering
Ochre Bio News & Media
New NYC 'Liver ICU' Lab Transforming Liver Disease Treatments
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has opened a unique perfusion 'Liver ICU' lab in the Alexandria Centre for Life Sciences. The 'Liver ICU' is capable of running multiple simultaneous...GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the undersOchre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease
OXFORD, England--(BUSINESS WIRE)--Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver diseaseOchre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics CEO and Immunocore Ltd and Chairperson of Avacta PLC
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ochre Bio
Sign Up For FreeTo access detailed company insights
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. The company uncover new biological pathways by using advances in 'deep phenotyping', and then study the company's medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines the company brings to... Read More
